



Arkansas Brain Matters Memory Clinic
Conway Regional Neuroscience Center

This past year we introduced the Arkansas Brain Matters memory clinic to take best advantage of the rapid advancements in Alzheimer's Disease diagnosis and treatment. We need your assistance in identifying patients with mild cognitive impairment or mild / early dementia, who might qualify for the new disease altering anti-amyloid treatments (Leqembi, Kisunla). The earlier in the disease that we can initiate these treatments, the more neurons we can save, and the more clinical benefits we will achieve. Alzheimer's patients can qualify if: cerebral amyloid is identified, they are not on anticoagulants, and if MMSE scores are 20-30 / 30 (yes, even MMSE 30/30 can qualify).

Besides memory referrals, how can you help?

PT217:

Phosphorylated-tau 217 is a blood biomarker for Alzheimer's disease that has revolutionized early detection of amyloid pathology. It is believed to become positive 3-8 years before developing dementia. This can be ordered through CRMC labs, as a Mayo send-out "PT217." Positive results represent a 96% specificity for Alzheimer's disease. Negative results have a 92% sensitivity (to rule out Alzheimer's disease). There is also an intermediate range result that is deemed to require further evaluation.

MRI brain, IcoBrain, Dementia protocol:

We have partnered with an AI platform, IcoMetrix, employing their IcoBrain software to further analyze our brain MRIs. This allows volumetric measurements, including of the hippocampus, and comparisons with age-matched norms. This has been a valuable tool in now objectively recognizing Alzheimer's patterns of atrophy, as well as monitoring anti-amyloid treatment. It is ordered as "MRI brain, IcoBrain, Dementia protocol."

We are pleased to accept referrals for any of your patients with memory concerns. However, we will be expediting appointments for those patients who have evidence of Alzheimer's via **PT217 (positive or intermediate)** or **MRI brain Dementia protocol**, particularly those with clinically mild symptoms. Please forward any of these results with your referral, when possible.

Thanks so much in advance and please reach out if I can answer any of your questions,

A handwritten signature in blue ink that reads "K Schluterman".

Keith Schluterman, MD